fbpx

Year

2017
During July, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants and the new issue of shares that was made in connection with the exercise of the over-allotment option, subsequent to the listing of the Company’s shares on Nasdaq Stockholm. As of July 31, 2017,...
In September 2015, the UN adopted 17 new Sustainable Development Goals to help us combat hunger, poverty, oppression and climate change up to 2030. However, if we are to reach the UN’s ambitious goals, we need new innovative solutions. To help meet this challenge, the Lundbeck Foundation has provided UNLEASH with funding of DKK 2...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES Carnegie Investment Bank AB (publ) (“Carnegie”) and ABG Sundal Collier AB (“ABGSC”) exercise the over-allotment option regarding...
Lund, Sweden, 11 July 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, announced today that one of the components of its pipeline projects focused on developing a new CERAMENT product capable of enhancing bone growth has been awarded...
Microbiome Diagnostics Partners (MDP) to focus on the development of novel microbiome-based diagnostics for IBD and liver diseases. ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Stockholm, 21 June, 2017  BONESUPPORT HOLDING AB (publ) (“BONESUPPORT” or the “Company”) hereby announces the outcome...
Financially, 2016 was a good year for the Lundbeck Foundation. According to the annual report, our profits grew to DKK 2.5 billion, net worth increased to DKK 61 billion and we awarded grants totalling almost half a billion Danish kroner to biomedical sciences research. But what were the stories behind the figures? Who did we...
June 13th, 2017 – OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK. Additionally, PsiOxus announced the opening of a new US facility in Plymouth Meeting near Philadelphia, Pennsylvania. This dual expansion will...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Stockholm, 11 June, 2017  The Board of Directors of BONESUPPORT HOLDING AB (publ) (“BONESUPPORT” or the...
Ness Ziona, Israel and Chapel Hill, NC –May 23, 2017 – Atox Bio today announced that the Phase 3 ACCUTE study, evaluating Reltecimod (previously AB103) in patients with Necrotizing Soft Tissue Infections, will continue as planned without modification based on the successful completion of a pre-specified futility analysis.  The recommendation was made by the independent...
1 4 5 6 7 8 9

News

Danish researchers provide proof: Caesarean sections can lead to asthma and allergies
12. November 2020
Brand-new medical treatment for cocaine addiction
10. November 2020
90 million to 18 Talented Researchers
19. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge